QUZYTTIR
Total Payments
$174,132
Transactions
179
Doctors
109
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2,350 | 1 | 1 |
| 2020 | $171,782 | 178 | 108 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $149,137 | 27 | 85.6% |
| Consulting Fee | $14,863 | 11 | 8.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,360 | 7 | 4.2% |
| Food and Beverage | $2,712 | 133 | 1.6% |
| Education | $60.50 | 1 | 0.0% |
Payments by Type
Research
$149,137
27 transactions
General
$24,995
152 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions | TerSera Therapeutics LLC | $149,137 | 0 |
Top Doctors Receiving Payments for QUZYTTIR — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Procedural Dermatology | Lawton, OK | $14.18 | 1 |
| , MD | Emergency Medicine | Oklahoma City, OK | $14.18 | 1 |
| , MD | Medical Oncology | Cape Girardeau, MO | $14.08 | 1 |
| , M.D | Internal Medicine | Tuscaloosa, AL | $14.02 | 1 |
| , M.D | Medical Oncology | Tuscaloosa, AL | $14.02 | 1 |
| , M.D | Hematology & Oncology | Tuscaloosa, AL | $14.02 | 1 |
| , M.D | Hematology & Oncology | Terre Haute, IN | $11.20 | 1 |
| , MD | Hematology & Oncology | Terre Haute, IN | $11.20 | 1 |
| , M.D | Internal Medicine | Asheboro, NC | $11.00 | 1 |
| , M.D | Hematology & Oncology | Asheboro, NC | $11.00 | 1 |
Ad
Manufacturing Companies
- TerSera Therapeutics LLC $174,132
Product Information
- Type Drug
- Total Payments $174,132
- Total Doctors 109
- Transactions 179
About QUZYTTIR
QUZYTTIR is a drug associated with $174,132 in payments to 109 healthcare providers, recorded across 179 transactions in the CMS Open Payments database. The primary manufacturer is TerSera Therapeutics LLC.
Payment data is available from 2020 to 2021. In 2021, $2,350 was paid across 1 transactions to 1 doctors.
The most common payment nature for QUZYTTIR is "Unspecified" ($149,137, 85.6% of total).
QUZYTTIR is associated with 1 research study, including "A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions" ($149,137).